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“The Hope of Progress” is the title of a collection of essays 
[1]  by  Peter  Medawar,  who  won  the  Nobel  Prize  in 
Physiology  or  Medicine  in  1960,  jointly  with  Frank 
McFarlane Burnet, for his research in immunology. The 
sentence from which the phrase is taken - “To deride the 
hope of progress is the ultimate fatuity, the last word in 
poverty of spirit and meanness of mind” - may strike us 
as overelaborate and flowery in this texting and blogging 
age when the analogous sentiment is expressed as “Yes 
we can”. But Medawar was remarkable for his clarity of 
thought, as well as for his (now unfashionable) elegance 
of  expression,  and  his  research  on  transplant  rejection 
led to the discovery of principles fundamental to modern 
immunology; so the phrase seems apt as a title for a new 
series that we are launching with three contributions on 
biology relevant to clinical problems.
Two  of  the  three  contributions  are  reviews  -  by 
Christopher  Lord  and  Alan  Ashworth  on  the  develop-
ment of new cancer therapeutic drugs [2], and by Amy 
McKee,  Megan  McLeod,  John  Kappler  and  Philippa 
Marrack [3] on adjuvants and vaccine development. The 
third is a new feature, a video Q&A (see [4]), in which 
Martin Raff explains his interest in, and delivers his views 
on  research  on  the  biological  basis  of  autism,  both  in 
video and in text format [5].
The rationalization of cancer therapy
Alan Ashworth and Christopher Lord are known for the 
ingenious application of poly(ADP-ribose) inhibitors to 
the treatment of BRCA-mutant tumors, an approach that 
migrated from laboratory bench to phase II clinical trials 
in less than five years. This work, an application of the 
synthetic lethal principle borrowed from genetic analysis 
and applied to tumor therapy, is described in their review, 
which traces the evolution of anti-cancer drugs from the 
cytotoxic  blunt  instruments  that  remain  the  principal 
weapons against cancer to date, through the more refined 
and sophis  ticated drugs - notably herceptin and imatinib 
- targeted at molecules known to be modified in specific 
tumors, and finally describes how an understanding of 
the workings of cells as a whole, and the entire panoply of 
changes  that  characterize  a  tumor  cell,  and  not  just  a 
single mutant molecule, will become the basis of drug 
treatment.
The design of vaccines
Vaccination, the first great empirical success of immuno-
logy,  has,  by  comparison  with  the  major  chemothera-
peutic  drugs,  the  properties  of  a  magic  bullet.  It  is  a 
remarkable  fact,  therefore,  that  despite  an  increasingly 
detailed  appreciation  of  the  workings  of  the  immune 
system, the effectiveness of vaccines is still not properly 
understood.  We  understand  that  vaccination  generates 
an  adaptive  immune  response,  usually  protective 
antibodies;  but  this  is  the  end  result  of  a  process  of 
several cell-cell interactions that determine, first, whether 
there is an immune response at all; and second, whether 
that  response  is  protective  for  a  given  pathogen.  The 
induction of these protective immune responses, as well 
as  how  they  are  amplified  and  tuned  (as  opposed  to 
targeted),  depends  upon  adjuvants,  which  can  be 
substances  added  to  a  vaccine,  or  can  be  properties 
inherent in an intact pathogen.
Tantalizingly, while some of the cellular responses and 
some  of  the  cell-cell  interactions  underlying  adjuvant 
effects  are  understood  in  principle,  this  understanding 
falls crucially short of allowing the design of vaccines to 
produce lasting immunity of the appropriate kind to all 
the  infectious  diseases  flesh  is  heir  to.  Some  vaccines 
induce reliable immunity that lasts for many years, while 
for some diseases there is no effective vaccine at all.
In their review, McKee et al. [3] discuss what is known 
of adjuvant effects, what remains to be discovered, and 
where the most promising paths to progress lie.
Research and reality
While research on the biological basis of vaccination and 
targets  for  tumor  therapy  can  justly  be  called  trans-
lational, it would be fairer to describe the genomics of 
psychiatric disease as pre-translational. This contentious 
field is touched on by Martin Raff, in the interview we 
recorded with him and which, with the edited transcript, 
is the third of the first three publications in the Hope of 
progress series. Alan Ashworth believes strongly in the 
critical importance of understanding the clinical reality  © 2010 BioMed Central Ltd
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of  the  cancers  whose  conquest  is  the  aim  of  research 
biologists, and thus the need to foster close collaboration 
between clinicians and laboratory scientists [2, 6]; and it 
is  notable  how  little  much  of  the  research  on  the 
molecular  and  cell  biology  underlying  clearly  clinical 
problems seems to reflect an awareness of the broader 
picture of the disease. In the third of our three Hope of 
progress  articles,  on  autism,  Martin  Raff  explicitly 
embraces all levels of description, from the behaviour of 
the autistic child to the single nucleotides upon whose 
polymorphisms current notions of the underlying genetic 
architecture are built. He can best speak for himself [5] 
on  how  the  autistic  phenotype(s)  might  be  reconciled 
with  a  genetically  determined  neurodevelopmental 
problem - autism being among the most heritable of the 
psychiatric disorders (and he would be the first to point 
out that he speaks on this as an interested - in both senses 
of  the  word  -nonpractitioner).  But  the  issues  that  he 
raises about the pursuit of that heritability are general to 
all  heritable  psychiatric  disorders  -  and  indeed  to 
genetically complex non-psychiatric disorders as well.
The genetic architecture of psychiatric disease
It has long been known on the basis of family studies and 
studies  of  twins  and  adopted  children  that  there  is  a 
heritable  component  in  psychiatric  disease,  and  given 
that psychiatric disease is common – schizophrenia for 
example affects up to 0.8% of the population – but does 
not seem to follow a Mendelian pattern of inheritance, a 
widely embraced notion has been that it is caused by the 
combined effects of a large number of common genetic 
variants  each  with  an  individually  small  effect.  This  is 
known as the common disease-common variant (CDCV) 
hypothesis.  The  alternative  proposition  is  that  these 
diseases  are  caused  by  rare  variants  with  large  effects, 
and they are common because there are many such rare 
variants,  which  arise  with  relatively  high  frequency  de 
novo.  The  case  for  rare  variants  with  large  effects  has 
been persuasively argued for schizophrenia by McClellan 
et  al.  [7]  and  by  Mitchell  and  Porteous  [8],  and  for 
complex traits in general by Goldstein [9]. One of the 
main  planks  in  the  argument  against  the  common 
disease-common variant hypothesis is that in genome-
wide association studies (GWAS) only a tiny percentage 
of the heritability can be explained by common single-
nucleotide  polymorphisms  (SNPs)  [10],  an  embarrass-
ment  that  is  discussed  by  John  Brookfield  in  a  Q&A 
article [11] published to accompany our Hope of Progress 
articles and in which he explains the population genetic 
issues  that  arise  in  the  interpretation  of  association 
studies. This makes the alternative hypothesis of many, 
highly  penetrative,  rare  mutations  in  many  different 
genes  attractive;  and  several  such  variants  with  strong 
effects have been found.
The two proposed mechanisms of heritability are not 
mutually  exclusive  however,  and  there  are  many 
possibilities:  Mitchell  and  Porteous  [8]  suggest,  for 
example, that common low-penetrance variants may be 
important  modifiers  of  the  effects  of  rare  high-pene-
trance ones. The contention arises because, first, the basis 
for  recent  claims  to  have  identified  common  variants 
underlying psychiatric disease is susceptible to challenge 
[8],  and  second,  the  two  mechanisms  have  different 
implications  for  research  strategy.  Under  the  common 
disease-common  variant  hypothesis,  the  appropriate 
strategy is to increase the sample sizes for the genomes 
scanned in association studies, for reasons explained by 
Brookfield in his Q&A article [11]. If on the other hand 
rare de novo variants of large effect are important, then it 
will  be  more  fruitful  to  identify  individual  families  in 
which such mutant genes may be identified, and genome-
wide scans of large populations are unlikely to be helpful 
because different genes are likely to be affected in different 
families.  (This  will  not  necessarily  mean  however  that 
different  families  will  have  distinct  disease  phenotypes: 
first, different affected genes may be on the same pathway; 
and  second,  one  of  the  most  astonishing  revelations  in 
those cases in which a variant gene of large effect has been 
identified  is  that  the  disease  phenotype  can  vary 
enormously  within  a  family,  embracing  diagnoses  as 
different as bipolar and schizophrenic psychoses.)
What next?
Eventually, it is reasonable to suppose, by one method or 
the other, variant genes at the root of these disorders will 
be identified and assigned to pathways, and the relative 
roles  of  highly  penetrant  and  small-effect  variants  will 
become  clear.  We  shall  then  be  left  with  a  deeper 
mystery: why is the concordance rate for schizophrenia 
in  monozygotic  -  and  therefore  genetically  identical  - 
twins, even if they are reared together, only about 50%? 
The  non-genetic  causes  of  psychiatric  disease  may 
perhaps be a question for the biology of systems.
Future  articles  in  the  Hope  of  progress  series  will 
address  what  genomics  can  offer  to  the  study  of  the 
response  to  infectious  disease,  the  problems  of 
vaccinating  children  in  undeveloped  countries,  and 
protein folding problems underlying neurological disease. 
The answer to the monozygotic twin mystery may have to 
wait for another series.
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